FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of general formula I:
,
as well as to pharmaceutical compositions based thereon, and to application for treatment of inflammatory or autoimmune diseases associated with aberrant B-cell proliferation.
EFFECT: new compounds with inhibitory activity against Btk are obtained.
27 cl, 2 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF DIHYDROBENZO[b][1,4]DIAZEPINE-2-ONE AS I mGluR2 ANTAGONISTS | 2002 |
|
RU2270197C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
| BENZYLAMINE DERIVATIVES | 2014 |
|
RU2660421C2 |
| PYRROLOPYRAZINE KINASE INHIBITORS | 2012 |
|
RU2673064C2 |
| PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2618529C2 |
| PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2648236C2 |
| COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
| SUBSTITUTED BENZIMIDAZOLES AND MEDICINAL AGENT BASED ON THEREOF | 2000 |
|
RU2261248C2 |
